## LISTING OF CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Claims 1-16 (Cancelled)

Claim 17 (Currently amended) A compound having the structure:


wherein:

(a) A<sup>1</sup> and A<sup>2</sup> are each, independently, selected from the group consisting of a hydrogen atom and a group having the structure:

$$\begin{cases} \begin{pmatrix} R^1 \\ C \\ R^1 \end{pmatrix} D^1 - D^2 - R^2 \\ x \end{cases}$$

with the proviso that at A<sup>1</sup> and A<sup>2</sup> are not both hydrogen atoms, and wherein:

- (i) each R<sup>1</sup> is independently selected from the group consisting of a hydrogen atom and a hydroxyl group;
- (ii) x is 0 or 1;
- (iii) each R<sup>2</sup> is independently selected from the group consisting of:



wherein:

(a) a is at least 2 to 10;

- (b) b is at least 2 to 10;
- (c) c is 1 to 3;
- (d) d is 1 to 3; and
- (e) R<sup>12</sup> and R<sup>13</sup> are each independently selected from the group consisting of hydrocarbon groups and substituted hydrocarbon groups; and
- (iv)  $D^1$  is -C(O)-; and,
- (v) D<sup>2</sup> is -NH-; and
- (b) A<sup>3</sup> has the structure:

wherein:

- (i) each R<sup>1</sup> is independently selected from the group consisting of a hydrogen atom and a hydroxyl group;
- (ii) t is from 0 to 6;
- (iii) D⁴ is -CH(R¹)-;
- (iv)  $D^5$  is  $-OR^6$ ; and
- (v) R<sup>6</sup> is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, an aromatic group, and a substituted aromatic group.

Claim 18 (Previously presented) The compound according to Claim 17 wherein x is 1.

Claim 19 (Previously presented) The compound according to Claim 17 wherein x is 0.

Claims 20-22 (Cancelled)

Claim 23 (Previously presented) The compound according to Claim 17 wherein t is 0 to 2.

Claim 24 (Previously presented) The compound according to Claim 17 wherein R<sup>6</sup> is a substituted aromatic group.

Claim 25 (Previously presented) A composition comprising:

- (a) the compound according to Claim 17; and
- (b) a pharmaceutically acceptable carrier.

Claim 26 (Previously presented) A method selected from the group consisting of treating multidrug resistance, inhibiting transport protein activity, and combinations thereof, comprising administering to a mammal in need of such treatment or inhibition an effective amount of the composition according to Claim 25.

Claim 27 (Previously presented) A method of inhibiting transport protein activity comprising contacting a cell with an effective amount of the composition according to Claim 25.